Rothschild Investment Corp IL continued to hold its stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,792 shares of the biopharmaceutical company’s stock at the end of the second quarter. Rothschild Investment Corp IL’s holdings in Intercept Pharmaceuticals were worth $580,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE acquired a new position in Intercept Pharmaceuticals during the first quarter worth $130,000. Quantbot Technologies LP acquired a new position in Intercept Pharmaceuticals during the first quarter worth $170,000. Aperio Group LLC acquired a new position in Intercept Pharmaceuticals during the second quarter worth $212,000. Finally, Pacer Advisors Inc. raised its position in Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares during the period. 83.93% of the stock is owned by institutional investors and hedge funds.
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) opened at 103.19 on Friday. Intercept Pharmaceuticals, Inc. has a 12 month low of $96.63 and a 12 month high of $172.95. The firm’s 50-day moving average price is $120.81 and its 200-day moving average price is $117.78. The stock’s market capitalization is $2.59 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analysts’ expectations of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business’s revenue for the quarter was up 459.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.14) EPS. On average, equities research analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.05) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/12/intercept-pharmaceuticals-inc-icpt-position-held-by-rothschild-investment-corp-il-updated-updated.html.
A number of research firms have recently weighed in on ICPT. Cowen and Company reaffirmed a “buy” rating and issued a $225.00 price objective on shares of Intercept Pharmaceuticals in a research note on Monday, April 24th. Cantor Fitzgerald reaffirmed an “underweight” rating and issued a $69.00 price objective (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 8th. Credit Suisse Group upped their price objective on Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a research note on Monday, May 15th. Finally, BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $203.67.
In related news, Director Daniel G. Welch sold 217 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now directly owns 3,710 shares in the company, valued at $470,279.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lisa Bright sold 698 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $110.73, for a total value of $77,289.54. Following the completion of the sale, the insider now directly owns 24,711 shares in the company, valued at approximately $2,736,249.03. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,575 shares of company stock worth $6,144,469. Insiders own 9.20% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.